- Investopedia•2 hours ago
Positive top-line data from an ongoing high-resolution imaging trial reinstates a promising outlook for treating cardiovascular disease with Repatha.
- PR Newswire•3 hours agoAmgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study
THOUSAND OAKS, Calif., Sept. 28, 2016 /PRNewswire/ -- Amgen (AMGN) today announced positive top-line results for erenumab (AMG 334) from A Phase 3, RandomIzed, double-blind, placebo-controlled Study to Evaluate the efficacy and safety of erenumab in migraine prevention (ARISE). Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to have a critical role in mediating the incapacitating pain of migraine. "People with episodic migraine lose a substantial part of their lives to migraine, and many face intolerable pain and physical impairment, frequently accompanied by a significant disruption of their daily activities.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||170.20 x 100|
|Ask||170.32 x 200|
|Day's Range||169.05 - 172.22|
|52wk Range||135.64 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.37|
|Avg Vol (3m)||2,857,300|
|Dividend & Yield||4.00 (2.31%)|